IMMUTEP LTD/S (NASDAQ:IMMP) Short Interest Update

IMMUTEP LTD/S (NASDAQ:IMMP) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 423,900 shares, an increase of 35.9% from the August 31st total of 311,900 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is currently 0.3 days.

A hedge fund recently raised its stake in IMMUTEP LTD/S stock. Morgan Stanley increased its stake in IMMUTEP LTD/S (NASDAQ:IMMP) by 651.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131,038 shares of the biotechnology company’s stock after buying an additional 113,595 shares during the quarter. Morgan Stanley owned approximately 0.34% of IMMUTEP LTD/S worth $94,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.90% of the company’s stock.

NASDAQ:IMMP traded down $0.04 during trading hours on Thursday, reaching $1.69. 73,896 shares of the stock were exchanged, compared to its average volume of 788,596. IMMUTEP LTD/S has a twelve month low of $0.53 and a twelve month high of $3.10. The firm has a 50 day moving average of $1.48 and a 200 day moving average of $1.23.

Separately, Alliance Global Partners initiated coverage on IMMUTEP LTD/S in a research report on Tuesday, September 22nd. They set a “buy” rating for the company.


Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells.

Featured Article: What is the definition of market timing?

Receive News & Ratings for IMMUTEP LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMUTEP LTD/S and related companies with's FREE daily email newsletter.